KLK14

(redirected from hK14)

KLK14

A gene on chromosome 19q13.3-q13.4 that encodes a serine  endopeptidase with a trypsin- and chymotrypsin-like substrate specificity, which may: activate/inactivate proteinase-activated receptors F2R, F2RL1 and F2RL3, as well as other kallikreins (e.g., KLK1, KLK3, KLK5 and KLK11); liquefy seminal clot by cleaving semenogelins SEMG1 and SEMG2 and activating KLK3; cleave desmoglein DSG1, resulting in shedding of superficial keratinocytes from the skin surface; and play a role in tumour progression by affecting growth, invasion and angiogenesis.
Mentioned in ?
References in periodicals archive ?
In the present study, we monitored the effects of hormone treatment on serum and urine concentrations of hK2, hK3, hK4, hK5, hK6, hK7, hK8, hK10, hK11, hK13, and hK14 in female-to-male transsexuals receiving high-dose testosterone treatment for 4-12 months.
ELISA assays used in the present study Coating/ Dynamic Detection Detection Range, Limit, Kallikrein Antibody ng/L ng/L Reference hK2 mono/mono 2000 6 (8) hK3 mono/mono 2000 1 (9) hK4 mono/poly 20 000 100 (10) hK5 mono/mono 25 000 100 (11) hK6 mono/mono 50 000 100 (12) hK7 mono/mono 20 000 200 (13) hK8 mono/mono 20 000 200 (14) hK10 mono/mono 20 000 50 (15) hK11 mono/mono 50 000 100 (16) hK13 mono/mono 20 000 50 (17) hK14 mono/poly 20 000 100 (18) Mono, monoclonal mouse antibody; poly, polyclonal rabbit antibody.
The Australian carrier is offering 800 economy class return tickets to Sydney from HKD2,500 for those who have spent HKD1,000, while 80 people can claim a business class ticket at HK14,500.
In this study, we examined the effect of hormone treatment on serum and urine concentrations of hK2 to hK8, hK10, hK11, hK13, and hK14, obtained from male-to-female transsexuals who were receiving combined estrogen and antiandrogen therapy.
No suppression by antiandrogens and either type of estrogen was noted for serum hK8, hK13, and hK14.
We found significant correlations between serum concentrations of hK2 and hK3 (positive) or hK10 (negative), between hK4 and hK13 or hK14 (both positive), between hK5 and hK6 (positive), and between hK7 and hK8, hK13, or hK14 (all positive).
Recombinant hK1, hK2, hK3, hK4, hK5, hK6, hK7, hK8, hK9, hK10, hK11, hK12, hK14, and hK15 proteins did not produce measurable readings, even at concentrations 1000-fold higher than that of hK13.
The cross-reactivities of other homologous proteins were also investigated using recombinant hK1, hK2, hK3, hK4, hK5, hK6, hK7, hK9, hK10, hK11, hK12, hK13, hK14, and hK15, all at a concentration of 1 mg/L (produced in-house).
No immunoreactivity was detected when hK1, hK2, hK3, hK4, hK5, hK6, hK7, hK9, hK10, hK11, hK12, hK13, hK14, and hK15 solutions (all at 1000 [micro]g/L) were measured with the developed assay for hK8.
The cross-reactivity of our assay with other kallikreins was determined by the use of purified, recombinant hK2 (250 [micro]g/L), hK3 (PSA; 1000 [micro]g/L), hK5 (1000 [micro]g/L), hK6 (2500 [micro]g/L), hK7 (1000 [micro]g/L), hK8 (1000 [micro]g/L), hK9 (1000 [micro]g/L), hK10 (1000 [micro]g/L), hK11 (1000 [micro]g/L), hK12 (1000 [micro]g/L), hK13 (1000 [micro]g/L), and hK14 (1000 [micro]g/L).
New gene Previous gene New protein symbol (a,b) symbol(s) symbol KLK1 KLK1 hK1 KLK3 KLK3 hK3 KLK2 KLK2 hK2 KLK4 PRSS17, KLK-L1, KLK4 hK4 KLK5 KLK-L2 hK5 KLK6 PRSS9 hK6 KLK7 PRSS6 hK7 KLKS PRSS19 hK8 KLK9 KLK-L3 hK9 KLK10 PRSSL1, hK10 KLK11 PRSS20 hK11 KLK12 KLK-L5 hK12 KLK13 KLK-L4 hK13 KLK14 KLK-L6 hK14 New gene symbol (a,b) Other protein names/symbols KLK1 Pancreatic/renal kallikrein, hPRK KLK3 Prostate-specific antigen, PSA KLK2 Human glandular kallikrein 1, hGK-1 KLK4 Prostase, KLK-L1 protein, EMSP1 KLK5 KLK-L2 protein, HSCTE KLK6 Zyme, protease M, neurosin KLK7 HSCCE KLKS Neuropsin, ovasin, TADG-14 KLK9 KLK-L3 protein KLK10 NES1 protein KLK11 TLSP/hippostasin KLK12 KLK-L5 protein KLK13 KLK-L4 protein KLK14 KLK-L6 protein New gene GenBank symbol (a,b) Accession No.